Axulin
Not specified
CommercialActive
Key Facts
Indication
Not specified
Phase
Commercial
Status
Active
About Housey Pharmaceutical Research Laboratories
Housey Pharma is a unique hybrid entity combining internal therapeutic development with a successful technology licensing business. Its core strategy involves leveraging proprietary, internally invented drug discovery platforms to advance its own pipeline while generating revenue through licensing agreements with major pharmaceutical companies like Novartis. The company's pipeline includes both prescription therapeutics and a marketed product, Axulin, and is supported by a leadership team and advisory board with deep industry and scientific expertise. Its dual model of platform licensing and product development positions it in both the technology and therapeutics sectors of biopharma.
View full company profileOther Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |